These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33667366)

  • 1. How to make a better T cell: in vivo CRISPR screens have some answers.
    Villa M; Stanczak MA; Pearce EL
    Cell; 2021 Mar; 184(5):1135-1136. PubMed ID: 33667366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer CRISPR Screens In Vivo.
    Chow RD; Chen S
    Trends Cancer; 2018 May; 4(5):349-358. PubMed ID: 29709259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
    Shifrut E; Carnevale J; Tobin V; Roth TL; Woo JM; Bui CT; Li PJ; Diolaiti ME; Ashworth A; Marson A
    Cell; 2018 Dec; 175(7):1958-1971.e15. PubMed ID: 30449619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo T cell CRISPR screens reveal immunotherapeutic targets.
    Bradley CA
    Nat Rev Cancer; 2019 Nov; 19(11):606. PubMed ID: 31492928
    [No Abstract]   [Full Text] [Related]  

  • 5. Transcriptional and epigenetic regulators of human CD8
    McCutcheon SR; Swartz AM; Brown MC; Barrera A; McRoberts Amador C; Siklenka K; Humayun L; Ter Weele MA; Isaacs JM; Reddy TE; Allen AS; Nair SK; Antonia SJ; Gersbach CA
    Nat Genet; 2023 Dec; 55(12):2211-2223. PubMed ID: 37945901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.
    Xiang M; Li H; Zhan Y; Ma D; Gao Q; Fang Y
    Mol Cancer; 2024 Apr; 23(1):73. PubMed ID: 38581063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the Next-Generation T Cell Therapies.
    Guo J; Xu C
    Cancer Cell; 2020 May; 37(5):627-629. PubMed ID: 32396857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Amplifications Cause False Positives in CRISPR Screens.
    Sheel A; Xue W
    Cancer Discov; 2016 Aug; 6(8):824-6. PubMed ID: 27485003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CRISPR Odyssey into Cancer Immunotherapy.
    Delgado E; Kiani S
    CRISPR J; 2020 Apr; 3(2):73-75. PubMed ID: 32315222
    [No Abstract]   [Full Text] [Related]  

  • 10. Decoding γδ T cell anticancer therapies: integrating CRISPR screens with tumor organoids.
    Zhou J; Wu M; Yang G
    Signal Transduct Target Ther; 2023 Nov; 8(1):423. PubMed ID: 37953309
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer Screens: Better Together.
    Pruett-Miller SM
    CRISPR J; 2020 Feb; 3(1):12-14. PubMed ID: 32091251
    [No Abstract]   [Full Text] [Related]  

  • 12. Too much and not enough: tuning human primary T cell cytokine signaling networks.
    Henrickson SE
    Sci Immunol; 2022 Mar; 7(69):eabo7677. PubMed ID: 35245087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR Screens: The Right Tool for the Job.
    Russell A
    CRISPR J; 2019 Feb; 2():9-11. PubMed ID: 31021228
    [No Abstract]   [Full Text] [Related]  

  • 15. Generation of novel Il2rg-knockout mice with clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9.
    Byambaa S; Uosaki H; Hara H; Nagao Y; Abe T; Shibata H; Nureki O; Ohmori T; Hanazono Y
    Exp Anim; 2020 Apr; 69(2):189-198. PubMed ID: 31801915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
    Wang YD; Liang QF; Li ZY; Zhao CY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Anti-CRISPR Tactics: No Success without Sacrifice.
    van Gent M; Gack MU
    Immunity; 2018 Sep; 49(3):391-393. PubMed ID: 30231980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Edited Immune Effectors: The End of the Beginning.
    Mo F; Heslop HE; Mamonkin M
    Mol Ther; 2020 Apr; 28(4):995-996. PubMed ID: 32203679
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer.
    Zhou P; Shi H; Huang H; Sun X; Yuan S; Chapman NM; Connelly JP; Lim SA; Saravia J; Kc A; Pruett-Miller SM; Chi H
    Nature; 2023 Dec; 624(7990):154-163. PubMed ID: 37968405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR Libraries and Screening.
    Poirier JT
    Prog Mol Biol Transl Sci; 2017; 152():69-82. PubMed ID: 29150005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.